Evidence map›Paper›PMID 35290653›Full record

ArticleTherapeutic innovation & regulatory science2022

Enhancing Patient Care II: The Clinical Impact of Medical Information Services.

Leena Jindia, Sharone Keane, Susan Wnorowski, Evelyn R Hermes-DeSantis

Open access · hybridAbstract read
In one paragraph

Article in Therapeutic innovation & regulatory science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Leena JindiaMedical Information Content Strategy & Innovation, Janssen Scientific Affairs, LLC, Titusville, NJ, USA. ljindia@its.jnj.com.ORCID 0000-0002-5782-3062
Sharone KeaneWorldwide Research and Development, Global Medical Information, Pfizer, Inc., New York, NY, USA.ORCID 0000-0002-3718-5091
Susan WnorowskiUS Medical Information, US Medical Affairs Division, Ipsen Biopharmaceuticals, Inc., Basking Ridge, NJ, USA.ORCID 0000-0002-9659-4784
Evelyn R Hermes-DeSantisResearch and Publications, phactMI, West Point, PA, USA.ORCID 0000-0001-5658-3899
Ipsen (France) · FRJanssen (United States) · USPfizer (United States) · USRutgers, The State University of New Jersey · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnderstanding the ways that healthcare providers (HCPs) utilize medical information received from the pharmaceutical industry is important so that the information can be tailored and customized to meet the HCPs needs. Additionally, this understanding supports the value of the information provided. The purpose of this study was to collect opinions of HCPs who recently requested information from a manufacturer's Medical Information (Med Info) Service. HCPs provided their opinions on the perceived quality, relevance, impact on patient care, and intended usage of information.

methodsHCPs who recently requested medical information from one of eight participating companies received a Survey Monkey link in the information response. Data collected included demographics, perceived quality, relevance, impact on patient care, and intended usage of the information. Data were analyzed via descriptive statistics.

resultsOver a 14-month period, 246 HCPs responded to the survey. Eight companies participated in the survey. Customer responses to the survey ranged from 2 to 97 per company. A total of 99 pharmacists, 68 physicians, 22 registered nurses, 21 nurse practitioners, 8 physician assistants, and 28 others participated in the survey. Most HCPs (208/227, 92%) contacted the company Med Info Group 1-5 times in the last six months and 67% (159/238) had been in practice greater than 10 years. Most HCPs rated the following quality areas as a 4 or 5 on a 5-point Likert scale: timeliness (195/225, 87%), trustworthiness (189/221, 86%), conciseness (185/221, 84%), clarity (180/222, 81%), relevance (178/223, 80%), and completeness (173/222, 78%). The most common reason for contacting Med Info Services was to advance knowledge or education (110/228, 48%). Additional reasons were at the point of care (60/228, 26%), for a specific patient (not at point of care) (60/228, 26%), and to reflect on a treatment decision (59/228, 26%). The relevance of the information provided was utilized for the HCPs own education (99/226, 44%), shared with peers (91/226, 40%), or used for future treatment decisions (88/226, 39%). The information provided enhanced patient care by enabling the HCPs to educate patients more effectively (86/222, 39%), efficacy of treatment regimen was enhanced (70/222, 32%), or other positive impact (65/222, 29%).

conclusionThe opinions of HCPs who are using Medical Information Services are overall positive. All the quality indicators were rated as a 4 or 5 by the majority of HCPs, with the lowest in completeness (173/222, 78%) and the highest in timeliness (195/225, 87%). Medical Information Services were utilized to advance knowledge/education of the HCP, followed closely by the care of a current or future patient. However, when queried on the relevant use of the information in their practice, the most common answers were for their own education or to share with peers. The impact on patient care was focused on enabling the HCP to educate patients more effectively. The value of medical information is difficult to quantify. Understanding the quality assessment, utilization, and the impact on patient care by HCPs can provide a broad descriptor of value. This study supports the value of the medical information responses provided by pharmaceutical companies to HCPs in their practice(s).

Indexed as

Health PersonnelPhysiciansHumansInformation ServicesPatient CareSurveys and QuestionnairesClinical impactHealthcare professionalMedical informationSurvey

Identifiers

PMID35290653
PMCPMC8964574
OpenAlexW4220864531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.